These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37505170)

  • 1. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
    Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
    Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 4. Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia.
    Li Y; Kan X
    Biochem Genet; 2024 Apr; 62(2):1136-1159. PubMed ID: 37561332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
    Tu H; Zhang Q; Xue L; Bao J
    Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
    Song Z; Su M; Li X; Xie J; Han F; Yao J
    BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cuproptosis-related genes for predicting the development of prostate cancer.
    Wang X; Chen X; Xu C; Zhou W; Wu D
    Open Med (Wars); 2023; 18(1):20230717. PubMed ID: 37711156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
    Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas.
    Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y
    Front Genet; 2022; 13():992995. PubMed ID: 36579333
    [No Abstract]   [Full Text] [Related]  

  • 12. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma.
    Xie XZ; Zuo L; Huang W; Fan QM; Weng YY; Yao WD; Jiang JL; Jin JQ
    World J Gastrointest Surg; 2024 Jun; 16(6):1803-1824. PubMed ID: 38983344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma.
    Wu Z; Huang Z; Zhou X; Gao C; Peng Z; Zheng X; Zhang Y; Du Z; Wu B
    Genomics; 2023 Nov; 115(6):110732. PubMed ID: 37866660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis-related genes signature and validation of differential expression and the potential targeting drugs in temporal lobe epilepsy.
    Yang X; Zhang X; Shen K; Wang Z; Liu G; Huang K; He Z; Li Y; Hou Z; Lv S; Zhang C; Yang H; Liu S; Ke Y
    Front Pharmacol; 2023; 14():1033859. PubMed ID: 37435496
    [No Abstract]   [Full Text] [Related]  

  • 16. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
    Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
    Front Genet; 2022; 13():939956. PubMed ID: 36105090
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
    Zhou C; Li C; Zheng Y; Huang X
    Front Oncol; 2022; 12():934076. PubMed ID: 36387247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.